{
    "organizations": [],
    "uuid": "9832c86041880a6b47df7879f874d7326228631a",
    "author": "Peter Loftus",
    "url": "https://www.wsj.com/articles/biogen-and-abbvie-take-multiple-sclerosis-drug-off-market-1520007411",
    "ord_in_thread": 0,
    "title": "Biogen and Abbvie Take Multiple Sclerosis Drug Off Market",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Drugmakers Biogen Inc. and AbbVie Inc. said Friday they are pulling their new multiple-sclerosis treatment Zinbryta from all global markets after several European patients suffered serious inflammatory brain disorders.\nThe European Medicines Agency, which regulates drugs in the European Union, said Friday it started an “urgent review” of the drug because eight MS patients experienced encephalitis and other brain inflammations after taking the injected drug. Seven were in Germany and one was in Spain.\n... ",
    "published": "2018-03-02T21:43:00.000+02:00",
    "crawled": "2018-03-03T04:46:09.014+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "drugmakers",
        "biogen",
        "abbvie",
        "said",
        "friday",
        "pulling",
        "new",
        "treatment",
        "zinbryta",
        "global",
        "market",
        "several",
        "european",
        "patient",
        "suffered",
        "serious",
        "inflammatory",
        "brain",
        "disorder",
        "european",
        "medicine",
        "agency",
        "regulates",
        "drug",
        "european",
        "union",
        "said",
        "friday",
        "started",
        "urgent",
        "review",
        "drug",
        "eight",
        "m",
        "patient",
        "experienced",
        "encephalitis",
        "brain",
        "inflammation",
        "taking",
        "injected",
        "drug",
        "seven",
        "germany",
        "one",
        "spain"
    ]
}